Copeland Capital Management LLC Has $68.27 Million Stock Position in Cognex Corporation $CGNX

Copeland Capital Management LLC reduced its stake in Cognex Corporation (NASDAQ:CGNX) by 1.0% during the 1st quarter, Holdings Channel reports. The fund owned 1,393,446 shares of the scientific and technical instruments company’s stock after selling 14,548 shares during the period. Cognex makes up about 1.5% of Copeland Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Copeland Capital Management LLC’s holdings in Cognex were worth $68,265,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. CIBC Private Wealth Group LLC grew its position in shares of Cognex by 74.8% in the third quarter. CIBC Private Wealth Group LLC now owns 764 shares of the scientific and technical instruments company’s stock valued at $35,000 after purchasing an additional 327 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Cognex by 402.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company’s stock valued at $27,000 after buying an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Cognex during the 4th quarter worth $39,000. Miller Global Investments LLC bought a new position in Cognex during the 4th quarter worth $39,000. Finally, Larson Financial Group LLC boosted its position in shares of Cognex by 202.7% in the fourth quarter. Larson Financial Group LLC now owns 1,105 shares of the scientific and technical instruments company’s stock valued at $40,000 after acquiring an additional 740 shares during the period. 88.12% of the stock is currently owned by institutional investors and hedge funds.

Cognex Stock Up 0.3%

NASDAQ CGNX opened at $64.07 on Friday. Cognex Corporation has a twelve month low of $33.45 and a twelve month high of $72.88. The company has a market capitalization of $10.66 billion, a price-to-earnings ratio of 76.27 and a beta of 1.49. The stock has a fifty day simple moving average of $65.23 and a 200 day simple moving average of $54.41.

Cognex (NASDAQ:CGNX) last announced its earnings results on Wednesday, May 6th. The scientific and technical instruments company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.25 by $0.09. Cognex had a return on equity of 10.89% and a net margin of 13.62%.The business had revenue of $268.44 million for the quarter, compared to analysts’ expectations of $245.98 million. During the same period in the prior year, the business posted $0.14 earnings per share. The firm’s revenue was up 24.3% on a year-over-year basis. Cognex has set its Q2 2026 guidance at 0.400-0.440 EPS. Research analysts expect that Cognex Corporation will post 1.48 earnings per share for the current fiscal year.

Cognex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were given a dividend of $0.085 per share. The ex-dividend date was Thursday, May 21st. This represents a $0.34 annualized dividend and a dividend yield of 0.5%. Cognex’s dividend payout ratio is presently 40.48%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Cognex from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup reissued a “neutral” rating and set a $72.00 target price (up from $68.00) on shares of Cognex in a report on Monday. Stephens increased their price objective on shares of Cognex from $65.00 to $75.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $75.00 price target on shares of Cognex in a report on Thursday, May 7th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $80.00 price objective (up from $70.00) on shares of Cognex in a research report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.31.

Insider Transactions at Cognex

In related news, VP Laura Ann Macdonald sold 41,600 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $65.56, for a total transaction of $2,727,296.00. Following the transaction, the vice president directly owned 5,258 shares of the company’s stock, valued at approximately $344,714.48. This represents a 88.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Darren Marc Long sold 20,252 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $66.34, for a total value of $1,343,517.68. Following the sale, the vice president owned 3,990 shares of the company’s stock, valued at approximately $264,696.60. This represents a 83.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 224,847 shares of company stock valued at $14,975,098 in the last quarter. 1.70% of the stock is currently owned by company insiders.

Cognex Profile

Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.

The company’s product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.